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Irritable bowel syndrome (IBS) is a common and potentially disabling gastrointestinal (GI) disorder 
that is subject to strong psychological influences particularly among more severe IBS patients. Little 
is known about the role of actionable lifestyle factors (e.g., obesity) that influence the trajectory of 
other chronic diseases. This study examined the associations between obesity and different aspects 
of illness experience among more severe IBS patients. We hypothesized that Body Mass Index 
(BMI) would positively correlate with worse health outcomes including more severe IBS symptoms, 
extraintestinal complaints, and emotional distress. At pretreatment baseline in a National Institutes 
of Health (NIH)-funded behavioral trial, 448 Rome-diagnosed IBS patients (MAGE  = 41; MBMI = 26, 
Female = 8%) were administered a test battery that included a variety of clinical (IBS symptom 
severity, fear of GI symptoms, BMI, etc.), and sociodemographic (e.g. age, etc.) variables. BMI was 
positively and significantly correlated with somatization (unexplained somatic complaints) but not 
IBS symptom severity or emotional distress. A series of moderated multiple regression analyses 
showed that the associations between BMI and somatization were moderated by the interaction 
between BMI and age, and fear of GI symptoms. Older patients with higher BMI reported higher 
levels of somatization and patients who were more fearful of GI symptoms were more likely to 
experience somatization if they also had a high BMI. These data highlight the relationship between 
lifestyle factors and extraintestinal symptoms among more severe IBS patients and the impact of 
both sociodemographic (age) and psychosocial (fear of GI symptoms) factors on this relationship.  
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Irritable bowel syndrome (IBS) is a chronic, oftentimes disabling 
gastrointestinal (GI) disorder characterized by abdominal pain associated with 
diarrhea and/or constipation. With a worldwide prevalence of 11% (Lovell & Ford, 
2012), IBS is the most common GI disorder seen by gastroenterologists and primary 
care physicians. The painful, unpredictable, and uncontrollable nature of IBS 
symptoms is a source of quality of life impairment comparable to life-threatening 
conditions such as diabetes mellitus and hepatitis (Enck et al., 2016). Beyond its 
personal toll, IBS exacts substantial economic costs, estimated at $US28 billion 
annually (Everhart & Ruhl, 2009). 
The illness burden of IBS is complicated by the absence of a reliable biomarker. 
For this reason, IBS is best understood as a biopsychosocial problem that involves 
the interplay of physiological, environmental, and psychological factors (Mayer, 
Labus, Tillisch, Cole, & Baldi, 2015). Psychological factors are believed to have a 
particularly strong impact on the health status of more severe IBS patients (van 
Tilburg, Palsson, & Whitehead, 2013). Research supporting the relationship between 
psychosocial processes and IBS have generally focused on negative aspects of 
patients' illness experience such as emotional distress, maladaptive coping, faulty 
threat appraisal, inadequate support systems, and childhood adversity. Much less 
research has focused on the role of lifestyle factors such as eating patterns, tobacco 
or alcohol use, sleep, and physical activity. These factors are important because they 
are actionable and have an established impact on the trajectory of chronic disease 
(Fortin et al., 2014). 
The purpose of this study was to assess the relationship between obesity and 
clinical aspects of illness experience of IBS patients. Physiologically, obesity is 
associated with alterations in GI motility (Xing & Chen, 2004), which is regarded as 
an important influence of symptom pathogenesis in IBS (Quigley, 2003). Motility 
refers to the rhythmic muscular contractions that propel ingested food from the 
mouth through the digestive tract (Chang & Leung, 2014). Motility disturbances 
have been described throughout the GI tract of IBS patients and have been 
hypothesized as a cause of alterations in bowel transit time (i.e., the interval between 
consumption of food and its elimination as feces) and defecatory symptoms such as 
constipation or diarrhea (Accarino, Azpiroz, & Malagelada, 1995). Patients with 
diarrhea-predominant IBS have an increased number of fast colonic contractions, 
whereas patients with constipation-predominant IBS have fewer high-amplitude 
propagated colonic contractions (Bazzocchi et al., 1990). Secondly, obesity may be 
understood as a chronic stressor that is manifested in dysregulation of the 
hypothalamic-pituitary-adrenal (HPA) axis and sympathetic nervous system (SNS). 
These systems, which together compose the two major branches of the central stress 
response system, can modulate mucosal immune function (Chang et al., 2009). An 
imbalance in these systems has been reported in stress-sensitive disorders like IBS 
(Dinan et al., 2006). Moreover, an imbalance in these systems can predispose some 
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individuals to negative mood states, such as depression and anxiety, which can 
aggravate IBS symptoms and other co-occurring somatic complaints. 
Psychologically, a significant proportion of obese patients experience heightened 
levels of stress (Scott, Melhorn, & Sakai, 2012). Chronic life stress is known to 
potentiate a greater preference for highly palatable energy and nutrient-dense 
"comfort" foods, namely those that are high in sugar and fat (Chandler-Laney et al., 
2007; Dallman et al., 2003). While these foods may, in the short-term, modulate 
negative emotions arising from stressful live events, they may in the longer term 
trigger IBS symptoms (Hayes, Fraher, & Quigley, 2014). Thus, the patient lacking 
adequate coping resources is caught between the desire to reduce unpleasant 
emotional and somatic sensations. Further, chronic social stress arising from poor 
interpersonal relationships has been identified as an environmental factor that may 
contribute to the development of obesity (Scott et al., 2012) and IBS (Lackner & 
Gurtman, 2004). 
Drawing from these data, we expected that more obese IBS patients, based on 
baseline BMI, would report worse health outcomes including more severe IBS 
symptoms, comorbid somatic complaints including somatization (the presentation of 
medically unexplained somatic complaints), and greater emotional distress. A 
secondary goal was to characterize the relationship between sociodemographic 







Participants included 448 patients recruited at two tertiary academic medical 
centers in Buffalo, NY and Chicago, IL, as part of a National Institutes of Health 
(NIH)-funded clinical trial, the details of which can be found elsewhere (Lackner et 
al., 2012). Of the 448 individuals in the sample, 358 were female, 90.4% self-
identified as white, average age was 41.37 years old (SD = 14.80), and the average 
income was $72 thousand per year. Participants were enrolled primarily through 
local media coverage, community advertising, and physician referral. To qualify, 
participants must have met Rome III IBS diagnostic criteria (Longstreth et al., 2006) 
without organic gastrointestinal disease as determined by a board-certified study 
gastroenterologist. Rome criteria define IBS as a recurrent abdominal pain or 
discomfort at least 3 days per month over the last 3 months that is associated with at 
least 2 of the following: 1) improvement with defecation, 2) onset associated with a 
change in stool form, or 3) onset associated with a change in the frequency of stool 
(Drossman, Corazziari, Talley, Thompson, & Whitehead, 2000). Because this study 
was conducted as part of a larger clinical trial of behavioral treatments for moderately 
to severely affected IBS patients (Lackner et al., 2012), participants must have also 
reported IBS symptoms of at least moderate intensity (i.e., symptom occurrence at 
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least twice weekly for 6 months and causing life interference). Subjects with a 
presence of comorbid organic GI illness that would adequately explain GI symptoms 
[i.e., inflammatory bowel disease (IBD) or colon cancer], developmental disability, 
current or past diagnosis of schizophrenia or other psychotic disorders, current 
diagnosis of depression with suicidal ideation, and current diagnosis of psychoactive 




After a brief telephone interview to determine whether participants were likely 
to meet basic inclusion criteria, patients were scheduled for a medical examination 
to confirm IBS diagnosis (Drossman et al., 2000; Longstreth et al., 2006) and 
psychometric testing that for the purposes of this study included the test battery 
described in detail below. Institutional review board approval (University at Buffalo 
and Northwestern University) and written, signed, informed consent were obtained 
before study initiation. The study was completed in full compliance with the 




Emotional Distress. The Brief Symptom Inventory (BSI-18; Derogatis, 2000) 
is an 18-item self-report screening inventory designed to assess respondents' level of 
psychological distress on three dimensions: somatization, depression, and anxiety. In 
the current study, only the somatization dimension of the BSI-18 was utilized. Items 
on this measure ask participants to rate how much they have been distressed or 
bothered in the past 7 days by the given symptom, using a 5-point Likert scale 
ranging from 0 (not at all) to 4 (extremely).  
IBS Symptom Severity. The Irritable Bowel Syndrome Symptom Severity 
Scale (IBS-SSS; Francis, Morris, & Whorwell, 1997) is a 5-item instrument used to 
measure the severity and frequency of abdominal pain, severity of abdominal 
distension, dissatisfaction with bowel habits, and interference with quality of life on 
a 100-point scale. The five items are summed with the total scores ranging from 0 to 
500, with higher scores signifying more severe IBS symptoms. 
Fear of GI Symptoms. The Visceral Sensitivity Index (VSI; Labus et al., 2004) 
is a 15-item self-report questionnaire designed to measure those unique aspects of 
fear, anxiety, and hypervigilance that can accompany misappraisals of visceral 
sensations and discomfort. Items on the VSI are totaled to yield a range of possible 
scores from 0 (no fear of GI symptoms) to 75 (strong fear of GI symptoms). This 
scale has demonstrated reliability and validity in a sample of IBS patients (Lackner 
et al., 2012). 
Body Mass Index (BMI). BMI is the most widely used measurement of obesity 
and was calculated based on self-reported weight and height (kg/m2) at pre-treatment 
baseline. 
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Sociodemographic Factors. General background information, including 
patient's age, relationship status, gender, race and ethnicity, education level, income, 





Characteristics of the sample and correlations between continuous variables are 
presented in Table 1. Although average BMI in the sample would be classified as 
overweight, there was a wide range of BMI scores in the sample with the lowest BMI 
being 16.50 and the highest being 79.30. Similarly, age was also widely dispersed 
ranging from 41 years of age to 70.  
Before examining our hypotheses in a regression framework, we first examined 
the univariate correlations between the two outcome measures of interests and the 
continuous predictor variables of age, BMI, and VSI. As can be seen in Table 1, 
symptom severity was not significantly correlated with BMI but was correlated with 
both VSI and with age. Somatization, however, was significantly correlated with 
BMI and with VSI but not with age.  
 
Table 1 
Means, Standard Deviations, and Correlations among Continuous Variables 
 M SD 1 2 3 4 5 
1. Age 41.37 14.80 -     
2. BMI 26.51 6.52 .22** -    
3. VSI 44.69 13.99 -.11* .01 -   
4. Symptom Severity 282.54 70.97 -.10* .01 .38** -  
5. Somatization 4.31 4.07 -.04 .17** .33** .28** - 
VSI = Visceral Sensitivity Index; BMI = Body Mass Index; M = Mean; SD = Standard Deviation. 
*p < .05; **p <.01.  
 
Predicting Symptom Severity and Somatization 
 
In order to examine how age, gender, BMI, and VSI are related to symptom 
severity and somatization, a series of stepwise moderated multiple regression analyses 
were conducted. Symptom severity and somatization were examined as the dependent 
measures in separate regression analyses. In each analysis, age, gender, VSI, and BMI 
were entered as predictors in the first step and all two-way interactions between those 
variables were entered in the second step. Because we were interested in how the 
interaction between BMI and VSI may be moderated by gender and age, we examined 
the only two three-way interactions in the third step of the equation that would address 
those questions: the interaction of age by BMI by VSI and the interaction of gender 
by BMI by VSI. Results of both analyses are presented in Table 2.  
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The first step of the multiple regression analysis predicting symptom severity 
from age, gender, BMI and VSI main effects was significant and accounted for 14% 
of the variability in symptom severity. The main effect of VSI was the only 
significant predictor in the first step of the regression analysis. When all the two-way 
interactions were entered in the second step, none significantly predicted symptom 
severity and there was no significant increase in variance accounted for in symptom 
severity, ΔR2 = .01, F(6, 421) = 0.69, p = .652. When the two three-way interactions 
of interest were entered in the third step, neither were significant predictors of 
symptom severity and there was no significant increase in variance accounted for in 




In the first step of the multiple regression analysis examining the main effects 
model, both BMI and VSI significantly predicted somatization. This model 
accounted for 13% of the variance in somatization. In the second step, two 
interactions significantly predicted somatization and the full model accounted for 
17% of the variance in somatization, a significant increase over the main effects 
model, ΔR2 = .04, F(6, 423) = 3.18, p < .01. Interactions were deconstructed using 
the procedures recommended by Aiken and West (1991) to graph the interactions 
and test the significance of simple slopes. When the interaction between age and BMI 
was graphed (see Figure 1), the shape of the interaction indicated that somatization 
was greater in high BMI patients, however, that difference between low and high 
BMI patients was more pronounced among older patients. The test of the simple 
slope for the relationship between BMI and somatization among older patients was 
significant, β = .71, t = 2.86, p < .01, with the greatest levels of somatization being 
among older patients with the highest BMI scores. However, the relationship of BMI 
to somatization among younger patients was not significant, β = .47, t = 1.75, p = 
.081. The second significant interaction was between BMI and VSI. Graphing this 
interaction and testing the simple slopes using the same procedures indicted that there 
was a significant relationship between BMI and somatization for those high on VSI, 
β = .70, t = 2.86, p < .01, but not among those low on VSI, β = .47, t = 1.78, p = 
.076. While visceral sensitivity also increased somatization, those who were high on 
visceral sensitivity and high on BMI reported the highest levels of somatization. 
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Figure 2. Interaction between BMI and VSI Predicting Somatization. VSI = Visceral 
Sensitivity Index; BMI = Body Mass Index. 
 
When the two three-way interactions of interest were entered in the third step, 
neither were significant predictors of somatization and there was no significant 
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The purpose of this study was to shed light on the relationship between obesity 
and health status of more severely affected IBS patients. We hypothesized that IBS 
patients with higher BMI would report worse health outcomes as evidenced by more 
severe gastrointestinal symptoms, comorbid extraintestinal complaints, and higher 
levels of emotional distress. We found mixed support for our hypotheses. The 
severity of IBS symptoms was significantly related to baseline BMI. Our most robust 
finding involved the relationship between somatization and both BMI and fear of GI 
symptoms as measured by the VSI. Somatization refers to medically unexplained 
bodily symptoms and has been thought to explain the frequent "extra-intestinal" 
symptoms of IBS (MacLean, Palsson, Turner, & Whitehead, 2012) and the high co-
occurrence between functional gastrointestinal disorders (FGIDs) and other 
functional somatic syndromes that are similarly defined by unexplained bodily 
symptoms (Whitehead et al., 2007). In research with another FGID, functional 
dyspepsia (FD), somatization has also been shown to be associated with GI 
sensorimotor processes including gastric sensitivity and gastric emptying as well as 
with impaired quality of life (Van Oudenhove et al., 2011) symptom severity and 
weight loss across the spectrum of functional gastroduodenal disorders (Clauwaert, 
2012), and may be a "risk factor" for the development of FD (Gathaiya, 2009). 
Higher levels of somatization correspond with heath care use and quality of life 
impairment (Spiegel, Kanwal, Naliboff, & Mayer, 2005) and predict a poor response 
to treatment (Porcelli, Fabbri, & Serretti, 2012), including increasing one's likelihood 
of discontinuing medication due to perceived adverse effects (Agosti, Quitkin, 
Stewart, & McGrath, 2002). In the case of our study, individuals with higher 
somatization levels reported stronger fears of GI symptoms. These data build on 
recently published research by Fergus, Limbers, Griggs, & Kelley (2018) who found 
that somatic complaints in a sample of obese patients was predicted by a set of factors 
including anxiety sensitivity (AS), which is conceptually and empirically related to 
visceral sensitivity (VS). Whereas AS taps into fear of arousal symptoms, VS 
measures fear of GI symptoms. Our data extend the work by Fergus et al. (2018) by 
examining the role of age and gender as well as the interactions between BMI and 
VS. Further research is needed to tease out the causal relationship between fear of GI 
symptoms, somatic complaints, and their underlying mediators (e.g., autonomic 
arousal, cognitive bias, etc.).  
To our knowledge, no prior research has linked VSI to BMI in IBS patients, 
although Hearon, Utschig, Smits, Moshier, and Otto (2013) has found that 
overweight/obese individuals reported significantly higher anxiety sensitivity (AS) 
than normal weight participants. The VSI is descriptively similar to the Anxiety 
Sensitivity Index (ASI) and data implicating AS as a potential risk factor for 
maladaptive eating behavior may be instructive for making sense of our findings. AS 
is a dispositional cognitive characteristic reflecting a tendency to fear anxiety and 
arousal-related symptoms (e.g., chest pain, racing heart, breathlessness) based on the 
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belief that they have catastrophic physical, mental, or social consequences (McNally, 
2002). The VSI has a more narrow focus denoting a tendency to fear GI symptoms. 
Individuals with high AS have a tendency to experience heightened levels of negative 
affect and a propensity to respond more strongly to negative emotions than their low 
AS counterparts (Otto, Pollack, Fava, Uccello, & Rosenbaum, 1995). Lacking an 
effective set of emotion regulation skills, high AS individuals tend to adopt more 
maladaptive coping strategies to modulate negative affect. These strategies can 
include emotional eating (eating to modulate negative affect) and avoidance or 
premature discontinuation of physical activities, particularly those that elicit some 
somatic discomfort (Hearon, Quatromoni, Mascoop, & Otto, 2014; Smits, Tart, 
Presnell, Rosenfield, & Otto, 2010). It is possible that VS governs eating behaviors 
and physical activity of IBS patients in much the same way that AS does. If so, 
heightened fear of GI symptoms may draw IBS patients into a vicious cycle that 
restricts them to sedentary indoor activities that affords them fewer opportunities for 
energy expenditure and more for energy intake. This formulation echoes reports of 
IBS patients who complain of engaging in fewer recreational activities due to fear of 
negative consequences (e.g., having an accident while exercising or lack of 
availability of a bathroom). Clinically, these data suggest possible avenues for 
improving the health and wellbeing of IBS patients through lifestyle interventions 
such as exercise. If fear of GI symptoms interferes with IBS patients' ability to engage 
in regular or sustained activity, then more robust treatments may depend on targeting 
these fears and resultant exercise avoidance through cognitive behavioral technique 
strategies. These strategies may include interoceptive exposure that emphasize 
habituation to threat related cues (Ljotsson et al., 2011).  
The relationship between BMI and somatization is complex on the basis of our 
data. As noted above, patients with higher BMIs reported higher levels of 
somatization. However, the difference between low and high BMI patients was more 
pronounced among older participants. That is, we found higher levels of somatization 
among older IBS patients with the highest BMI scores. Traditionally, somatization 
among the elderly has been viewed as a form of masked depression (Sheehan & 
Banerjee, 1999). The interaction between age and BMI suggests that the relationship 
may not necessarily be a physical manifestation of psychiatric conditions but rather 
reflective of broader health problems that often afflict many older adults. As their 
health deteriorates and physical activity declines, elderly individuals may be forced 
to make lifestyle changes that sets the stage for increased somatic complaints. 
Warwick & Salkovskis (1990) have developed a cognitive behavioral model of 
somatization that emphasizes cognitive processes including selective attention to 
bodily sensations, catastrophic interpretation of benign symptoms, and reliance on 
avoidance behaviors (e.g., reassurance-seeking) to cope with medically unexplained 
symptoms. These factors interact and fuel one another in a reciprocal manner. Their 
impact may be intensified by aspects of aging such as frailty, reduced social support 
that would otherwise buffer them from pathogenic effects of stress (Cohen & Wills, 
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1985), compromised physical functioning, and an increased sense of vulnerability in 
the face of worsening health (Charles & Carstensen, 2010).  
Generally speaking, our data underscore the importance of extraintestinal 
symptoms as part of the illness experience in more severe IBS patients. Up to two-
thirds of IBS patients report non-GI symptoms compared to less than 15% of healthy 
individuals (Whorwell, McCallum, Creed, & Roberts, 1986). Some comorbid 
physical disorders include a cluster of benign medical syndromes such as interstitial 
cystitis, chronic pelvic pain, migraine and/or tension headaches, and fibromyalgia 
that are disproportionately associated with IBS (Whitehead et al., 2007). Others 
include more well-defined physical illnesses such as hypertension and arthritis 
(Lackner, Gudleski, & Blanchard, 2004; Whitehead et al., 2007). IBS is associated 
with significant mental comorbidity as well. In studies (Lackner et al., 2013) that 
have administered structured clinical interviews to establish the extent of psychiatric 
comorbidity per criteria as specified in the Diagnostic and Statistical Manual of 
Mental Disorders (American Psychiatric Association, 1994), approximately 60% of 
treatment-seeking IBS patients have a diagnosable psychiatric condition (Blanchard, 
Keefer, Payne, Turner, & Galovski, 2002), with generalized anxiety disorder and 
depression being the most common disorders. By comparison, approximately 25% 
of American adults suffer from diagnosable mental disorders (Alegria, Jackson, 
Kessler, & Takeuchi, 2003; Kessler et al., 2004). Comorbidity influences illness 
experience of IBS in a variety of ways. Levy et al. (2001) found that the majority of 
healthcare charges in patients are for extraintestinal medical conditions. More 
recently, Lackner et al. (2013) found that medical and psychiatric comorbidity is 
associated with increased distress, worse physical and mental functioning and quality 
of life impairment and, for patients with specific clusters of physical and mental 
conditions (e.g., depression, generalized anxiety disorder, low back pain, insomnia) 
more severe IBS symptoms. Our data add to this line of research by showing that 
lifestyle factors (e.g., obesity) and sociodemographic factors (e.g., age) may impact 
coexisting physical complaints, particularly medically unexplained ones, of IBS 
patients.  
Results should be interpreted in light of study limitations. Because our data are 
cross-sectional and correlational, we do not intend to suggest that findings 
demonstrate causal relationships among obesity and IBS-related health outcomes. At 
best, our data can be construed as suggestive of a possible causal relationship that 
could be confirmed through future longitudinal analyses. Our data reflected a subset 
of treatment-seeking individuals who were willing to enroll in a behaviorally-based 
randomized controlled trial. Therefore, our findings may not necessarily generalize 
to less psychologically oriented patients or those from primary care settings or 
community populations (i.e., non-consulters) representative of the majority of 
individuals with symptoms compatible with IBS. Furthermore, because of the 
relative demographic homogeneity of our selected sample of patients who were 
mostly White, female, chronically ill, and educated, our results may not be 
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generalizable to a broader, more diverse population. Although our measures satisfy 
accepted standards for psychometric soundness, data is based on self-report, which 
means that they are subject to some bias and measurement error. However, we do 
not believe that our reliance on self-report invalidates our findings. The meaning of 
our findings could have been increased with the addition of a control group of non-
consulting individuals with IBS symptoms or those with organic GI disease (e.g., 
IBD). Lastly, because BMI was based on self-report, we may have underestimated 
actual levels of obesity.  
In spite of these imperfections, we believe that these data contribute to what is 
known about the impact of actionable lifestyle factors on illness experience of IBS 
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Correlatos del índice de masa corporal en los pacientes moderados  




SII es un trastorno gastrointestinal común y potencialmente incapacitante, susceptible a las 
influencias psicológicas fuertes, especialmente entre los pacientes más graves. Se sabe poco sobre 
el papel de los factores del estilo de vida (p.ej. obesidad) que influyen en la trayectoria de otras 
enfermedades crónicas. Este estudio ha examinado la correlación entre la obesidad y los diferentes 
aspectos de la experiencia de enfermedad en los pacientes más graves con el SII. Nuestra hipótesis 
fue que el SII se podría correlacionar positivamente con peores resultados de salud, incluyendo 
síntomas más graves del SII, molestias extraintestinales y angustia emocional. Durante el 
pretratamiento, en una prueba de comportamiento basada en NIH, 448 pacientes con el SII 
diagnosticados mediante los criterios de Roma (MEDAD = 41, MIMC = 26, F = 8%) fueron 
sometidos a una batería de prueba que incluía una variedad de variables clínicas (gravedad del SII, 
miedo de síntomas gastrointestinales, IMC etc.) y sociodemográficas (p. ej. edad etc.) El IMC fue 
positiva y significativamente correlacionado con la somatización (molestias somáticas 
inexplicadas), pero no con la gravedad de los síntomas del SII o angustia emocional. Una serie de 
múltiples análisis regresivos moderados demostró que la relación entre el IMC y la somatización 
fue moderada por la interacción entre el IMC, la edad y el miedo de los síntomas gastrointestinales. 
Los pacientes mayores con el IMC más alto mostraron niveles de somatización más altos, y los 
pacientes que tenían más miedo de los síntomas gastrointestinales tenían más posibilidad de sufrir 
la somatización si tenían también el IMC alto. Estos datos subrayan la relación entre los factores de 
estilo de vida y los síntomas extraintestinales entre los pacientes más graves con el SII, tanto como 
el impacto que tienen factores sociodemográficos (edad) y psicosociales (miedo de los síntomas 
gastrointestinales) en su relación.  
 
Palabras clave: síndrome del intestino irritable, trastorno gastrointestinal, índice de masa 
corporal, sensibilidad visceral, somatización 
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